Current possibilities in diagnosis and treatment of diffuse large B cell lymphoma in children and adolescents: results of Pediatric Hematology and Oncology Research Institute of N.N.Blokhin Russian Cancer Research Center, international experience
- Authors: Levashov AS1, Kovrigina AM2, Valiev TT1, Belyaeva ES1, Popa AV1, Mentkevich GL1
-
Affiliations:
- Pediatric Oncology and Hematology Research Institute of N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
- National Research Center for Hematology of the Ministry of Health of the Russian Federation
- Issue: Vol 17, No 4 (2015)
- Pages: 34-44
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/27022
- ID: 27022
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
A S Levashov
Pediatric Oncology and Hematology Research Institute of N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
Email: andreyslevashov@mail.ru
науч. сотр. отд-ния химиотерапии гемобластозов НИИ детской онкологии и гематологии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 2
A M Kovrigina
National Research Center for Hematology of the Ministry of Health of the Russian Federationд-р биол. наук, проф., зав. патологоанатомическим отд-нием ФГБУ ГНЦ 125167, Russian Federation, Moscow, Novyi Zykovskii pr., d. 4
T T Valiev
Pediatric Oncology and Hematology Research Institute of N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federationд-р мед. наук, ст. науч. сотр. отд-ния химиотерапии гемобластозов НИИ детской онкологии и гематологии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 2
E S Belyaeva
Pediatric Oncology and Hematology Research Institute of N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federationканд. мед. наук, врач отд-ния химиотерапии гемобластозов НИИ детской онкологии и гематологии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 2
A V Popa
Pediatric Oncology and Hematology Research Institute of N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federationд-р мед. наук, зав. отд-нием химиотерапии гемобластозов НИИ детской онкологии и гематологии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 2
G L Mentkevich
Pediatric Oncology and Hematology Research Institute of N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federationд-р мед. наук, проф., зав. отд-нием химиотерапии гемобластозов и детским отд-нием трансплантации костного мозга НИИ детской онкологии и гематологии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 2
References
- Reiter A. Diagnosis and Treatment of Childhood Non-Hodgkin Lymphoma. Hematology 2007; 1: 285-96.
- Burkhardt В, Oschlies I, Klapper W. Non-Hodgkin’s lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia. 2011; 25: 153-60.
- Ковригина А.М., Пробатова Н.А. Лимфома Ходжкина и крупноклеточные лимфомы. М.: Медицинское информационное агентство, 2007; с. 212.
- Swerdlow S.H, Campo E, Harris N.L. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, Fourth edition. 2008.
- Reiter A, Klapper W. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br J Hematol 2008; 142: 329-47.
- Jaffe E.S, Pittaluga S. Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. Hematology 2011; p. 506-14.
- Heerema N.A, Bernheim A.B, Lim M.S. Meeting report, State of the art and future needs in cytogenetic/molecular genetics/arrays in childhood lymphoma: summary report of workshop at the first international symposium on childhood and adolescent non-Hodgkin lymphoma. Ped Blood Cancer 2005; 45: 616-22.
- Oschlies I, Klapper W, Zimmermann M. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal - center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Francfurt-Munster) multicenter trial. Blood 2006; 107 (10): 4047-52.
- Miles R, Raphael M, Mc Carthy K. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c - myc protein expression, and a high incidence of germinal center subtype: report of the French-American-British (FAB) International Study Group. Ped Blood Cancer 2008; 51 (3): 369-74.
- Roschewski M, Staudt L.M, Wilson W.H. Diffuse large B-cell lymphoma - treatment approaches in the molecular era. Nat Rev Clin Oncol 2014; 11 (1): 12-23.
- Schneider C, Pasqualucci L, Dalla-Favera R. Molecular pathogenesis of diffuse large B-cell lymphoma. Semin Diagn Pathol 2011; 28: 167-77.
- Барышников А.Ю., Валиев Т.Т., Губин А.Н. Лимфомы у детей: практическое руководство. Под ред. Г.Л.Менткевича, С.А.Маяковой. М.: Практическая медицина, 2014.
- Менткевич Г.Л., Маякова С.А. Лимфомы у детей. М.: Практическая медицина, 2014.
- Laver J.H, Kraveka J.M, Hutchison R.E. Advanced-Stage Large-Cell Lymphoma in Children and Adolescents: Results of a Randomized Trial Incorporating intermediate-Dose Methotrexate and High-Dose Cytarabine in the Maintenance Phase of the APO Regimen: A Pediatric Oncology Group Phase III Trial. J Clin Oncol 2005; 23 (3): 541-7.
- Tsurusawa M, Mori T, Kikuchi A. Improved treatment results of Children with B-cell non-Hodgkin lymphoma: a report from Japanese pediatric leukemia/lymphoma study group B-NHL03 study. Ped Blood Cancer 2014; 61: 1215-21.
- Goldman S, Smith L, Anderson J.R. Rituximab and FAB/LMB96 chemotherapy in children with stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology group report. Leukemia 2013; 27: 1174-7.
- Barth M.J, Goldman S, Smith L. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukemia: a Children’s Oncology group report. Br J Haematol 2013; 162: 678-83.
- Самочатова Е.В., Шелихова Л.Н., Мякова Н.В. Возможности и проблемы современной терапии неходжкинских лимфом у детей и подростков. Педиатрия. 2011; 90 (4): 37-43.
- Самочатова Е.В., Шелихова Л.Н., Белогурова М.Б. Комбинированная химиоиммунотерапия больных неходжкинскими лимфомами из зрелых В-клеток возрастной группы до 18 лет: результаты многоцентрового исследования НХЛ2004м с применением ритуксимаба и модифицированного протокола Б-НХЛ БФМ 90. Онкогематология. 2009; 3: 4-14.
- Самочатова Е.В., Шелихова Л.Н., Мякова Н.В. Лечение диффузной Б-крупноклеточной лимфомы у детей с применением интенсивной химиотерапии с ритуксимабом: предварительные результаты. Детская онкология. 2007; 3-4: 51-6.
- Klapper W, Kreuz M, Kohler C.W. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood 2012; 119 (8): 1882-7.
- Chen Y, Sun X.F, Cai R.Q. Germinal - center type B-cell classification and clinical characteristics of Chinese pediatric diffuse large B-cell lymphoma: a report of 76 cases. Chin J Cancer 2013; 32 (10): 561-6.
- Poirel H.A, Cairo M.S, Heerema N.A. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Leukemia 2009; 23 (2): 323-31.
- Reiter A, Schrappe M, Tieman M. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster group Trial NHL-BFM90. Blood 1999; 94 (10): 3294-306.
- Woessmann W, Seidemann K, Mann G, Zimmermann M. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM group study NHL-BFM95. Blood 2005; 105: 948-58.
- Meyer P.N, Fu K, Greiner T.G. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011; 29 (2): 200-7.
- Perry A.M, Zdravko M. Biological prognostic markers in diffuse large B-cell lymphoma. Cancer Control 2012; 19 (3): 214-26.
- Culpin R.E, Sieniawski M, Angus B. Prognostic significance of immunohistochemistry - based markers and algorithms in immunochemotherapy - treated diffuse large B cell lymphoma patients. Histopathology 2013; 63: 788-801.
- Visco Y, Li Y, Xu-Monette Z.Y. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Prorram Study. Leukemia 2012; 26 (9): 2103-13.
- Cox C.M, Di Napoli A, Scarpino S. Clinicopathologic characterization of diffuse large B cell lymphoma with an associated serum monoclonal IgM component. PLOS one 2014. http://www.plosone.org/article/fetchObject.action?uri=info:doi/ 10.1371/journal.pone.0093903&representation=PDF
- Hu S, Xu-Monette Z.Y, Balasubramanyam A. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013; 121: 2715-24.
- Hu S, Xu-Monette Z.Y, Tzankov A. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high - risk gene expression signatures: a report from the international DLBCL Rituximab-CHOP consortium program. Blood 2013; 121 (20): 4021-31.
- Ichikava S, Fukuhara N, Katsushima H. Association between BACH2 expression and clinical prognosis in diffuse large B cell lymphoma. Cancer Sci 2014; 105 (4): 437-44.
- Laurent C, Do C, Gascoyne R.D. Anaplastic lymphoma kinase - positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol 2009; 27 (25): 4211-6.
- Miyazaki K, Yamaguchi M, Suzuki R. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 2011; 22: 1601-7.
- Nam S.J, Go H, Paik J.H. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leukemia Lymphoma 2014; 55 (11): 2466-76.
- Ok C.J, Xu-Monette Z.Y, Tzankov A. STAT3 expression and clinical inplications in de novo diffuse large B cell lymphoma: a report from the International DLBCL Rituximab-CHOP consortium program. Blood 2013; 122 (21). https://ash.confex.com/ash/2013/webprogram/Paper60938.html.
- Ok C.Y, Chen J, Xu-Monette Z. Clinical implications of phosphorylated STAT3 expression in de novo diffuse large B-cell lymphoma. Clinical Cancer Res 2014; 20 (19): 5113-23.
- Tzankov A, Xu-Monette Z, Gerhard M. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathol 2014; 27: 958-71.
- Valera A, Colomo L, Martinez A. ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements. Modern Pathol 2013; 26: 1329-37.
- Visco C, Tzankov A, Xu-Monette Z. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP consortium program study. Haematologica 2013; 98 (2): 255-63.
- Wu Z.L, Song Y.Q, Shi Y.F. High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J Hematol Oncol 2011; 4 (31). http://www.jhoonline.org/content/pdf/1756-8722-4-31.pdf
- Xie M, Wei Y, Ley Y. The prognostic significance of tumor - associated macrophages and NK cells in patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2014; 124 (21). http://www.bloodjournal.org/content/124/21/5390.full.pdf
- Yamamoto W, Nakamura N, Tomita N. Human leukocyte antigen - DR expression on flow cytometry and tumor associated macrophages in diffuse large B cell lymphoma treated by: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cogort study. Leukemia/Lymphoma 2014; 55 (12): 2721-7.
- Imbach P, Kuhne Th, Arceci R. Pediatric Oncology. A comprehensive guide. 2006; p. 61-9.
- Rosolen A, Perkins S.L, Pinkerton C.R. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol 2015; 33 (18): 2106-11.
- Apostolopoulos D.J, Papandrianos N.I, Symeonidis A. Technetium-99m depreotide imaging by single photon emission tomography/low resolution computed tomography in malignant lymphomas: comparison with gallium-67 citrate. Ann Nuclear Med 2010; 24: 639-47.
- Bardi E, Csoka M, Garai I. Value of FDG-PET/CT examinations in different cancers of children, focusing on lymphomas. Pathol Oncol Res 2014; 20: 139-43.
- Dabaja B, Phan J, Mawlawi O. Clinical implications of PET-negative residual CT masses after chemotherapy for diffuse large B-cell lymphoma. Leukemia Lymphoma 2013; 54 (12): 2631-8.
- Furth C, Steffen I.G, Erdrich A.S. Explorative analyses on the value of interim PET for prediction of response in pediatric and adolescent non-Hodgkin lymphoma patients. EJNMMI res 2013; 3 (71). http://www.ejnmmires.com /content/3/1/71
- Lange J, Burghardt B. Treatment of adolescents with aggressive B-cell malignancies: the pediatric experience. Curr Hematol Malign Rep 2013; 8 (3): 226-35.
- Scott R, Jo-Anne V, Aliakbar S. Characteristic expression patterns of TCL1, CD38, CD44 identify aggressive lymphomas harboring a MYC translocation. Am J Surg Pathol 2008; 32 (1): 113-22.
- Green T.M, Nielsen O, de Stricker K. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol 2012; 36 (4): 612-9.
- Kondratieva S, Duraisamy S, Unitt C.L. Aberrant expression of the dendritic cell marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediastinal large B-cell lymphoma distinguishes these tumor types from morphologically and phenotypically similar lymphomas. Am J Surg Pathol 2011; 35 (10): 1531-9.
- Togunaga T, Tomita A, Sugimoto K. De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry - positive and flow cytometry - negative phenotype: molecular mechanisms and correlation with rituximab sensitivity. Cancer Sci 2014; 105 (1): 35-43.
- Song G, Cho W.C, Gu L. Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Med Oncol 2014; 31 (56). http://link.springer.com.sci-hub.org/article/10.1007/s12032-014-0056-y
- Fen Liu, Ding H, Jin X. FCGR3A 158 V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma. DNA Cell Biol 2014; 33: 616-23.
- Morschhauser F.A, Cartron G, Thieblemont C. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle - cell lymphoma: results from the Phase II GAUGUIN study. J Clin Oncol 2013; 31: 2912-9.
- Coiffier B, Radford J, Bosly A. A multicentre, phase II trial ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. Br J Hematol 2013; 163: 334-42.
- Viardot A, Goebeler M, Hess G. Treatment of relapsed/refractory diffuse large B cell lymphoma with the bispecific T-cell engager (BiTE) antibody construct blinatumomab: primary analysis results from an open - label, phase II study. ASH annual meeting abstracts book. 2014; 4460. https://ash.confex.com/ ash/2014/webprogram/Paper 68589. Html
- Portell C.A, Wenzell C.M, Advani A.S. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol Adv Appl 2013; 5: 5-11.
- Schlegel P, Lang P, Zugmaier G. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica 2014; 99 (7): 1212-8.
- Stackelberg A, Locatelli F, Zugmaier G. Phase 1/2 study in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) receiving blinatumomab treatment. ASH annual meeting abstracts book. 2014; 2292. https://ash.confex. com/ash/ 2014/webprogram/Paper69576.html
- Schuster F.R, Stanglmaier M, Woessmann W. Immunotherapy with trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in pediatric high - risk patients with recurrent CD20-positive B-cell malignancies. Br J Haematol 2015; 169 (1): 90-102.
- Kochenderfer J.N, Dudley M.E, Kassim S.H. Chemotherapy - refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T-cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2014. http://jco.ascopubs.org/content/early/2014/08/25/JCO. 2014.56.2025. full.pdf
- Wang Y, Zhang W.Y, Han Q.W. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor - modified T cells. Clin Immunol 2014; 155: 160-75.
- Maude S.L, Teachey D.T, Porter D.A. Chimeric antigen receptor (CAR) modified N cells induce durable remissions in children with relapsed/refractory ALL. Blood 2015; 125 (26): 4017-23.